morab028
mAbexperimental
Clinical trial activity
2 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started May 1, 2010 (NCT01123304)
Timeline
2010s
- Jan 1, 2010
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
Mechanism of action
- Disialoganglioside GD2CROSS-LINKING AGENT
Disialoganglioside GD2 cross-linking agent
- Disialoganglioside GD2Immunity, passive
Disialoganglioside GD2 immunity, passive
Chemistry & pharmacology
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL2109416 ↗
Also known as
- morab028
- morab-028
- morab-028
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT01212276 | Phase 1 | Dec 1, 2010 | Cornell University, Morphotek |
| NCT01123304 | Phase 1 | May 1, 2010 | Morphotek |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Morphotek | For profit | 2 | 2 | 1 | 2010 |
| Cornell University | Academic/Hospital | 1 | 0 | 1 | 2010 |
2 organizations
Page 1 / 1